Risk Factors for Idiosyncratic Drug-Induced Liver Injury
- 30 June 2010
- journal article
- review article
- Published by Elsevier BV in Gastroenterology
- Vol. 138 (7), 2246-2259
- https://doi.org/10.1053/j.gastro.2010.04.001
Abstract
No abstract availableKeywords
This publication has 152 references indexed in Scilit:
- Epidemiology of Idiosyncratic Drug-Induced Liver InjurySeminars in Liver Disease, 2009
- Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sexJournal of Hepatology, 2009
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirThe New England Journal of Medicine, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)British Journal of Pharmacology, 2007
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005
- Liver Injury during Highly Active Antiretroviral Therapy: The Effect of Hepatitis C CoinfectionClinical Infectious Diseases, 2004
- Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.JCI Insight, 1988
- Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinateDigestive Diseases and Sciences, 1982